Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Have been diagnosed with plaque psoriasis for at least 6 months.

• Have plaque psoriasis covering at least 15% of their total body.

• Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment).

• Be willing and able to comply with scheduled visits, treatment plan and other study procedures.

Exclusion Criteria:

• Currently have non-plaque forms of psoriasis or drug-induced psoriasis.

• Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy.

• Subject is participating in another trial using an investigational agent or procedure.

• Women who are pregnant or breast-feeding or considering becoming pregnant.